Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, UBS Group Analyst Says

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lifted by stock analysts at UBS Group from $615.00 to $640.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the pharmaceutical company’s stock. UBS Group‘s price objective points to a potential upside of 19.73% from the stock’s current price.

Several other equities analysts have also weighed in on VRTX. Morgan Stanley started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $665.00 price objective on the stock. Canaccord Genuity Group increased their target price on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. Evercore boosted their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 2nd. Stifel Nicolaus increased their price objective on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the stock a “hold” rating in a research report on Tuesday. Finally, Daiwa Securities Group raised their target price on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $589.48.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded down $18.63 during midday trading on Tuesday, reaching $534.52. The stock had a trading volume of 903,115 shares, compared to its average volume of 1,386,724. Vertex Pharmaceuticals has a twelve month low of $403.16 and a twelve month high of $568.67. The stock has a market capitalization of $135.66 billion, a PE ratio of 31.19, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. The stock’s 50-day simple moving average is $523.32 and its 200 day simple moving average is $479.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the firm posted $4.80 EPS. Equities analysts predict that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $11,975,849,000. Bank of America Corp DE acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $1,509,651,000. Legal & General Group Plc acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $928,893,000. Bank of New York Mellon Corp purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $830,842,000. Finally, Deutsche Bank AG purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $784,391,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.